Cargando…
Evolution of acquired resistance in a ROS1(+) KRAS G12C(+) NSCLC through the MAPK pathway
Patients with metastatic NSCLC bearing a ROS1 gene fusion usually experience prolonged disease control with ROS1-targeting tyrosine kinase inhibitors (TKI), but significant clinical heterogeneity exists in part due to the presence of co-occurring genomic alterations. Here, we report on a patient wit...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9871013/ https://www.ncbi.nlm.nih.gov/pubmed/36690705 http://dx.doi.org/10.1038/s41698-023-00349-0 |